14.09.2014 09:00:10
|
ReWalk Robotics Ltd. Announces Pricing of Initial Public Offering
YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Sept. 14, 2014 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (ReWalk), an innovative medical device company that designs, develops and markets wearable robotic exoskeletons for individuals with spinal cord injury, today announced the pricing of its initial public offering of 3,000,000 ordinary shares, at a price of $12.00 per share. ReWalk's ordinary shares are expected to begin trading on September 12, 2014 on the NASDAQ Global Market under the ticker symbol "RWLK." The offering is expected to close on September 17, 2014, subject to the satisfaction of customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 450,000 ordinary shares at the initial public offering price.
ReWalk expects to receive total estimated net proceeds from this offering of approximately $31.3 million after deducting estimated underwriting discounts and commissions and estimated offering expenses. ReWalk intends to use the net proceeds from the offering for general corporate purposes including sales and marketing expenditures aimed at growing the business and research and development expenditures focused on product development.
Barclays Capital Inc. and Jefferies LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. is acting as co-manager for the offering.
The offering is being made only by means of a prospectus, copies of which can be obtained from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Ave, Edgewood, NY 11717, 888-603-5847, email: Barclaysprospectus@broadridge.com or Jefferies LLC, 520 Madison Ave, 2nd Floor, New York, NY 10022, 877-547-6340, email: Prospectus_Department@Jefferies.com.
A registration statement relating to these securities has been filed and declared effective by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the offered securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. (formerly Argo Medical Technologies Ltd.) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the US, Israel and Germany. CONTACT: Lisa Wilson In-Site Communications, Inc. Investor Relations T: (212) 452-2793 E: lwilson@insitecony.com
This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ReWalk Robotics Ltd. via Globenewswire
HUG#1855760
ReWalk expects to receive total estimated net proceeds from this offering of approximately $31.3 million after deducting estimated underwriting discounts and commissions and estimated offering expenses. ReWalk intends to use the net proceeds from the offering for general corporate purposes including sales and marketing expenditures aimed at growing the business and research and development expenditures focused on product development.
Barclays Capital Inc. and Jefferies LLC are acting as joint book-running managers for the offering. Canaccord Genuity Inc. is acting as co-manager for the offering.
The offering is being made only by means of a prospectus, copies of which can be obtained from: Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Ave, Edgewood, NY 11717, 888-603-5847, email: Barclaysprospectus@broadridge.com or Jefferies LLC, 520 Madison Ave, 2nd Floor, New York, NY 10022, 877-547-6340, email: Prospectus_Department@Jefferies.com.
A registration statement relating to these securities has been filed and declared effective by the U.S. Securities and Exchange Commission. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the offered securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. (formerly Argo Medical Technologies Ltd.) develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury. ReWalk's mission is to fundamentally change the health and life experiences of individuals with spinal cord injury. Founded in 2001, ReWalk has headquarters in the US, Israel and Germany. CONTACT: Lisa Wilson In-Site Communications, Inc. Investor Relations T: (212) 452-2793 E: lwilson@insitecony.com
This announcement is distributed by Nasdaq OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ReWalk Robotics Ltd. via Globenewswire
HUG#1855760
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu ReWalk Robotics Ltdmehr Nachrichten
11.11.24 |
Ausblick: ReWalk Robotics stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net) | |
14.08.24 |
Ausblick: ReWalk Robotics veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net) |